173 related articles for article (PubMed ID: 32380752)
1. Peptide Interference with APP and Tau Association: Relevance to Alzheimer's Disease Amelioration.
Maron R; Armony G; Tsoory M; Wilchek M; Frenkel D; Arnon R
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380752
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease.
Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM
BMC Neurosci; 2019 Mar; 20(1):13. PubMed ID: 30894120
[TBL] [Abstract][Full Text] [Related]
3. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
Wu X; Kosaraju J; Zhou W; Tam KY
ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
[TBL] [Abstract][Full Text] [Related]
5. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.
Dai CL; Chen X; Kazim SF; Liu F; Gong CX; Grundke-Iqbal I; Iqbal K
J Neural Transm (Vienna); 2015 Apr; 122(4):607-17. PubMed ID: 25233799
[TBL] [Abstract][Full Text] [Related]
6. Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20-APP transgenic and wild-type mice.
Tapia-Rojas C; Inestrosa NC
J Neurochem; 2018 Feb; 144(4):443-465. PubMed ID: 29240990
[TBL] [Abstract][Full Text] [Related]
7. Amyloid Precursor Protein and Tau Peptides Linked Together Ameliorate Loss of Cognition in an Alzheimer's Disease Animal Model.
Maron R; Vinik Y; Tsoory M; Wilchek M; Arnon R
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569901
[TBL] [Abstract][Full Text] [Related]
8. A small molecule transcription factor EB activator ameliorates beta-amyloid precursor protein and Tau pathology in Alzheimer's disease models.
Song JX; Malampati S; Zeng Y; Durairajan SSK; Yang CB; Tong BC; Iyaswamy A; Shang WB; Sreenivasmurthy SG; Zhu Z; Cheung KH; Lu JH; Tang C; Xu N; Li M
Aging Cell; 2020 Feb; 19(2):e13069. PubMed ID: 31858697
[TBL] [Abstract][Full Text] [Related]
9. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
10. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
[TBL] [Abstract][Full Text] [Related]
11. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
12. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.
Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA
J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868
[TBL] [Abstract][Full Text] [Related]
13. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
14. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
[TBL] [Abstract][Full Text] [Related]
15. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
16. Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in Mice.
Ghosal K; Fan Q; Dawson HN; Pimplikar SW
PLoS One; 2016; 11(7):e0159435. PubMed ID: 27459671
[TBL] [Abstract][Full Text] [Related]
17. Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner.
Lecordier S; Pons V; Rivest S; ElAli A
Front Immunol; 2021; 12():813536. PubMed ID: 35173711
[TBL] [Abstract][Full Text] [Related]
18. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
Guo Q; Li H; Cole AL; Hur JY; Li Y; Zheng H
PLoS One; 2013; 8(11):e80706. PubMed ID: 24278307
[TBL] [Abstract][Full Text] [Related]
19. Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages.
Serrano FG; Tapia-Rojas C; Carvajal FJ; Cisternas P; Viayna E; Sola I; Munoz-Torrero D; Inestrosa NC
Curr Alzheimer Res; 2016; 13(9):1017-29. PubMed ID: 26502813
[TBL] [Abstract][Full Text] [Related]
20. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
